The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors.

Kou, Wen; Lin, Yan Yan; Su, Fei; Xiang, Yue; Qiao, Hui; Wu, Xin'An; Hou, Xiao-Ming

Kou, Wen; Lin, Yan Yan; Su, Fei; Xiang, Yue; Qiao, Hui; Wu, Xin'An; Hou, Xiao-Ming.

Afiliação

Kou W; Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Lin YY; Department of General Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Su F; Department of Oncology, First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Xiang Y; United States Food and Drug Administration, Silver Spring, MD, United States.
Qiao H; Department of Oncology, First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Wu X; Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Hou XM; Department of Oncology, First Hospital of Lanzhou University, Lanzhou, Gansu, China.

Front Pharmacol ; 13: 910722, 2022.

Article em En | MEDLINE | ID: mdl-36330095